Nektar Therapeutics

Oncotelic Therapeutics, Inc.

Kimberly Perkins

J Milton Harris

Mei-chang Kuo

John S Patton

Chester Leach

Blaine Bueche

David J Chaplin

Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.

Use of VDAS to enhance immunomodulating therapies against tumors

The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.

Compositions of chemically modified insulin

Pulmonary administration of chemically modified insulin

Growing community of inventors

Belmont, CA, United States of America

Kimberly Perkins